Which pathway addresses a weight-loss plateau?
Plateaus are read against the current pathway. GLP-1 titration is reviewed at the recalibration window; testosterone or BHRT may be added in parallel when hormonal biomarkers match.
Full answer
Weight-loss plateaus are expected and read against the current pathway. Provider review evaluates GLP-1 titration, side-effect tolerability, protein and resistance-training adherence, sleep, and hormonal context at the recalibration window. Men with newly confirmed low testosterone may be evaluated for TRT in parallel; peri/menopausal women may be evaluated for BHRT. Tirzepatide may be considered for candidates plateauing on semaglutide within provider review. Every adjustment is synchronous-video reviewed.
Educational. Not a substitute for individualized provider review.
- Glp1 Semaglutide pathway — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29